Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant

NCT01539083 is registered in ClinicalTrials.gov with Janssen Scientific Affairs, LLC as lead sponsor.

NCT NCT01539083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01539083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant
Lead sponsor
Janssen Scientific Affairs, LLC
Phase
Phase 3
Overall status
Completed
Start date
January 13, 2012
Completion date
January 9, 2018
Enrollment
256 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma